33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: MyCare-009-05
    Meeting Abstract

    Moffat, G. T.; Watson, D.; Kapoor, S.; Roy, K. G. G.; Parashar, R.; Alam, A.; Alam, A.; Tyagi, A.; Singh, D.; Kumari, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms
    Meeting Abstract

    Minev, B.; Santidrian, A. F.; Minev, I.; Nguyen, D.; Zamarin, D.; Marincola, F.; Draganov, D. D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab
    Meeting Abstract

    Miller, K.; Filippova, O. T.; Hayes, S. A.; Abu-Rustum, N.; Aghajanian, C.; Broach, V.; Ellenson, L. H.; Jewell, E. L.; Kyi, C.; Lakhman, Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Baseline blood parameters as predictive biomarkers of immunotherapy efficacy in solid tumors
    Meeting Abstract

    Marra, A.; Criscitiello, C.; Morganti, S.; Viale, G.; Zagami, P.; Nicolo, E.; Ferraro, E.; Repetto, M.; Tarantino, P.; D'Amico, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex)
    Meeting Abstract

    Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Otero, P. R.; Leleu, X.; Hiemenz, J. W.; Hassoun, H.; Touzeau, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer
    Meeting Abstract

    Marth, C.; Vulsteke, C.; Perez, M. J. R.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials
    Meeting Abstract

    McQuade, J. L.; Hammers, H. J.; Furberg, H.; Engert, A.; Andre, T.; Blumenschein, G.; Tannir, N. M.; Baron, A. D.; Larkin, J.; El-Khoueiry, A. B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • An analysis of trends in prostate cancer treatment from a CMS database
    Meeting Abstract

    Konski, A. A.; Jewell, E. L.; Havrilesky, L. J.; Efstathiou, J. A.; Johnstone, P. A.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively
    Meeting Abstract

    Malla, M.; Huebner, L. J.; Piawah, S.; Lenz, H. J.; Blanke, C. D.; Meyerhardt, J. A.; O'Reilly, E. M.; Shi, Q.; Venook, A. P.; Goldberg, R. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
    Meeting Abstract

    Mar, N.; Friedlander, T. W.; Hoimes, C. J.; Flaig, T. W.; Bilen, M. A.; Balar, A. V.; Henry, E.; Srinivas, S.; Rosenberg, J. E.; Petrylak, D. P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save